StocksMedium•19 October 2026•
1 min read
GSK Lung Cancer Drug Achieves 61% Response Rate in Early-Stage Trial
Key Facts
1GSK's experimental drug risvutatug rezetecan showed a 61% confirmed response rate in patients with relapsed extensive-stage small cell lung cancer.
GSK's experimental drug risvutatug rezetecan demonstrated a 61% confirmed response rate in patients with relapsed extensive-stage small cell lung cancer. Proactive Investors reported that 11 out of 18 patients receiving an 8mg dose responded to the treatment, significantly outperforming the 32% response rate observed in the 6mg dose group.
The company stated that these results support its decision to utilize the higher dose in its ongoing global Phase III study, noting that the safety profile remained manageable despite serious adverse events in 42% of the high-dose group. GLAXF closed at $24.44 on October 16, 2026.